Year-end Sale % OFF 
Abstract
Octreotide is particularly useful in patients with resistant acromegaly and some gastroenteropancreatic (GEP) tumours, e.g. VIPomas, carcinoids and glucagonomas. The efficacy of octreotide can be attributed to its action regarding somatostatin receptors on GEP tumour cells. The symptoms of these tumours are due to a greater extent to the peptides they secrete than to their actual size. In most patients these symptoms improve or disappear completely with octreotide treatment. Side effects of treatment are mainly mild and do not necessitate withdrawal of the treatment. Octreotide is currently the drug of choice for controlling the symptoms of inoperable GEP tumours.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
